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OBJECTIVES We examined the clinical, angiographic, and procedural characteristics determining survival
after percutaneous coronary intervention (PCI) for cardiogenic shock.
BACKGROUND The SHOCK (SHould we emergently revascularize Occluded coronaries for Cardiogenic
shocK?) trial prospectively enrolled patients with shock complicating acute myocardial
infarction (MI). Patients were randomized to a strategy of early revascularization or initial
medical stabilization.
METHODS Patients randomized to early revascularization underwent PCI or bypass surgery on the basis
of predefined clinical criteria. Patients randomized to early revascularization who underwent
PCI and had angiographic films available for analysis are the subject of this report (n  82).
RESULTS The median time from MI to PCI was 11 h. The majority of patients had occluded culprit
arteries (Thrombolysis In Myocardial Infarction [TIMI] grade 0 or 1 flow in 62%) and
multivessel disease (81%). One-year mortality in PCI patients was 50%. Mortality was 39%
if PCI was successful but 85% if unsuccessful (p  0.001). Mortality was 38% if TIMI flow
grade 3 was achieved, 55% with TIMI grade 2 flow, and 100% with TIMI grade 0 or 1 flow
(p  0.001). Mortality was 67% if severe mitral regurgitation was documented. Independent
correlates of mortality were as follows: increasing age (p  0.001), lower systolic blood
pressure (p  0.009), increasing time from randomization to PCI (p  0.019), lower
post-PCI TIMI flow (0/1 vs. 2/3) (p  0.001), and multivessel PCI (p  0.040).
CONCLUSIONS Restoration of coronary blood flow is a major predictor of survival in cardiogenic shock.
Benefit appears to extend beyond the generally accepted 12-h post-infarction window.
Surgery should be considered in shock patients with severe mitral insufficiency or multivessel
disease not amenable to relatively complete percutaneous revascularization. (J Am Coll
Cardiol 2003;42:1380–6) © 2003 by the American College of Cardiology Foundation
Retrospective studies suggest that early percutaneous coro-
nary intervention (PCI) may improve outcome in patients
with cardiogenic shock (1–5). The randomized SHOCK
(SHould we emergently revascularize Occluded coronaries
for Cardiogenic shocK?) trial showed that a strategy of
See page 1387
early revascularization, either with surgery or PCI as
deemed appropriate by the treating cardiologist, increased
one-year survival from 34% to 47% (p  0.025) compared
with initial aggressive medical therapy in patients with
shock due to left ventricular dysfunction complicating acute
myocardial infarction (MI) (6). In this report, we examine
the clinical, angiographic, and procedural characteristics and
relationship to late mortality for patients undergoing PCI in
the early revascularization arm of the SHOCK trial.
METHODS
Trial design. The SHOCK trial enrolled patients in 36
centers between 1993 and 1998 (6–8). Eligible patients had
predominant left ventricular dysfunction resulting in cardio-
genic shock within 36 h of MI. Patients were randomly
assigned within 12 h of shock diagnosis to initial medical
stabilization or emergency revascularization.
The SHOCK trial protocol recommended PCI of the
infarct-related artery if patients had one- or two-vessel
coronary artery disease. Percutaneous coronary intervention
was also recommended if patients had three-vessel disease
but the non-culprit vessel stenosis was 90% or supplied
small branch vessels. It was recommended that PCI be
performed only on the infarct-related artery.
Emergency coronary artery bypass grafting was recom-
mended for patients with left main coronary artery stenosis
50%, patients with stenoses 90% in two non-culprit
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major vessels, patients in whom PCI was unsuccessful or
who had disease unsuitable for PCI. It was also recom-
mended that patients with three-vessel coronary artery
disease who had successful PCI of a culprit stenosis be
evaluated for subsequent coronary bypass surgery during the
same hospitalization. Although these recommendations
were made, the choice of revascularization procedure was
individualized and decided solely by the site physicians.
A total of 302 patients were enrolled in the SHOCK trial.
Of these, 152 patients were randomly assigned to emer-
gency revascularization (Fig. 1). Twenty of these patients
did not undergo revascularization because of rapid death,
minor disease, or unsuitable anatomy. Thus, revasculariza-
tion was attempted in 132 patients: initial coronary artery
bypass in 48 patients and initial PCI in 84. Eight PCI patients
subsequently underwent bypass surgery within 24 h of PCI,
which was either unsuccessful or performed as a bridge to
surgery. A total of 82 patients randomly assigned to emergency
revascularization and selected for PCI (excluding two addi-
tional patients for whom the angiographic film was unavailable
for analysis) are the subject of this report.
Angiographic core laboratory. Angiograms were reviewed
at the core laboratory (New York Hospital/Cornell Medical
Center) by two independent, blinded readers. Discrepancies
were resolved by a third reader. Thrombolysis In Myocar-
dial Infarction (TIMI) criteria (9), an estimate of the
amount of myocardium at risk based on the coronary artery
jeopardy score (10) and other standard criteria were used
(11–13). Significant coronary disease was defined as 50%
diameter stenosis. A significant stenosis of the left main
coronary artery was counted as two-vessel disease if the left
coronary was non-dominant and as three-vessel disease if
dominant, as well as left main disease. Percutaneous coro-
nary intervention success was defined as the combination of
a residual stenosis50%, a20% reduction in stenosis, and
TIMI 2 or 3 flow.
Statistical methods. The distributions of categorical vari-
ables were compared using Fisher exact test, and the
distributions of ordered categorical variables, such as TIMI
flow and the year PCI was performed, were compared using
the Mantel-Haenszel test for linear trend. Group differences
in continuous variables were compared using Student’s t test
for comparisons of age and heart rate, and the Wilcoxon
rank sum test for the remaining variables. Thirty-day and
one-year survival curves were estimated by the Kaplan-
Meier method. The log-rank (to assess group differences in
overall survival) and Wilcoxon test (to evaluate whether
there was group difference in early deaths) were used to
compare Kaplan-Meier survival estimates. One-year sur-
vival was also analyzed using Cox proportional hazards
regression. The survival time of one patient was censored at
the time of heart transplantation. Variables such as baseline
characteristics, clinical management, hemodynamic and an-
giographic findings, and outcomes found in Tables 1, 2, and
3 with a Cox regression univariate p value 0.20 were
grouped and entered into intermediate models. The covari-
ates with significant p values from these models were then
combined to determine a final model with covariate p values
0.05. All analyses were conducted using the Statistical
Analysis System (SAS, Cary, North Carolina) and S-Plus
(Seattle, Washington).
Abbreviations and Acronyms
GP  glycoprotein
MI  myocardial infarction
PCI  percutaneous coronary intervention
SHOCK  SHould we emergently revascularize
Occluded coronaries for Cardiogenic shocK
TIMI  Thrombolysis In Myocardial Infarction
Figure 1. Flowchart of SHOCK Trial patients. CABG  coronary artery bypass graft surgery; PCI  percutaneous coronary intervention.
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RESULTS
Patient sample. The PCI patient and clinical characteris-
tics by vital status at one year are presented in Table 1. The
median time from MI to shock was 5.1 h and from MI to
PCI was 11 h. Survivors were seven years younger, on
average, than non-survivors. Only 15% (3/20) of patients
who underwent PCI after an episode of cardiopulmonary
resuscitation survived for one year.
Angiographic findings. Core laboratory angiographic
findings are shown in Table 2. The majority of patients
had multivessel disease (81%). The culprit lesion was
most frequently in the left anterior descending artery (50%)
and was usually severely stenotic or occluded (mean diam-
eter stenosis 95  8%). Survivors had higher ejection
fractions than non-survivors (34  11 vs. 27  7, p 
0.025). Initial culprit artery patency (TIMI flow grade 2 or
3) was present in 38%, with normal coronary flow (TIMI 3)
in 21% of patients. Flow was absent or severely reduced
(TIMI 0 or 1) in 62%. There was a 45% one-year survival
rate for initial occlusion (TIMI 0 or 1), and a 58% one-year
survival rate for initial patency (TIMI 2 or 3 flow) (p 
0.363).
PCI procedure. The most common complication (8.5%)
occurring in the catheterization laboratory was an arrhyth-
mia requiring urgent treatment. Death in the catheteriza-
tion laboratory occurred in 3.7% (3 patients). Although 81%
of patients had multivessel disease, most PCI patients
underwent single-vessel procedures (87%). During the study
period there was an increase in the frequency of multivessel
procedures from 0% in 1993 to 1994, to 10% in 1995 to
1996 and 23% in 1997 to 1998 (p  0.018). Stents were
implanted in the culprit artery in 28 patients (34%). The
culprit artery stenting rate increased during the study from
0% in 1993 to 1994, to 10% in 1995 to 1996 to 74% in 1997
to 1998 (p  0.001). Percutaneous coronary intervention
was more often successful in stented than unstented patients
(93% vs. 67%, p  0.013), although one-year survival was
similar (54% vs. 48%, p 0.82) (Fig. 2). Glycoprotein (GP)
IIb/IIIa (abciximab) use increased during the study period
from 0% during 1993 to 1994, to 7% between 1995 to 1996
and 81% from 1997 to 1998 (p  0.001).
PCI outcome. Overall survival in the 82 patients selected
for PCI was 54% (n  44) at 30 days and 50% (n  41) at
one year. Percutaneous coronary intervention success was
achieved in 76%. Thirty-day survival was 65% after success-
ful PCI but only 20% if unsuccessful (p  0.001). At one
year, these values were 61% and 15%, respectively (p 
0.001). There were 17 patients with final post-PCI stenosis
Table 1. Baseline Characteristics and Clinical Management of Patients Assigned to Early Revascularization and Undergoing PCI in
the SHOCK Trial by One-Year Survival Status
Characteristic
All PCI Patients
(n  82)
Survivors
(n  41)
Nonsurvivors
(n  41) p Value
Age (yrs) 65  10 62  10 69  10 0.001‡
Male gender 62% 71% 54% 0.171
Diabetes 25% 27% 24% 0.800
History of congestive heart failure 5% 2% 8% 0.353
History of renal insufficiency 5% 5% 5% 1.000
History of MI 23% 22% 24% 1.000
History of cardiac surgery 4% 5% 2% 1.000
History of PCI 9% 10% 8% 1.000
History of peripheral vascular disease 14% 15% 14% 1.000
Lowest systolic blood pressure (mm Hg)* 67  12 67  12 66  12 0.299‡
Pulmonary wedge pressure (mm Hg)† 25  8 24  8 26  7 0.271‡
Cardiac index (l/min/m2)† 1.8  0.6 1.8  0.4 1.8  0.8 0.228‡
Systolic blood pressure (mm Hg)† 89  21 93  22 85  20 0.086‡
Heart rate (beats/min)† 100.9  22.3 96.5  21.7 105.6  22.2 0.068‡
Median time from MI to shock (h) 5.1 (2.0, 10.5) 5.5 (2.0, 12.0) 5.0 (2.1, 10.5) 0.809‡
MI to shock 6 h 54% 51% 56% 0.825‡
Median time from MI to PCI (h) 11.0 (6.1, 19.5) 12.0 (6.0, 19.5) 9.9 (6.2, 22.3) 0.917‡
Median time from SHOCK to PCI (h) 5.3 (3.0, 7.7) 4.8 (2.7, 7.3) 5.5 (3.5, 8.7) 0.212‡
Median time from randomization to PCI (h) 0.9 (0.3, 2.0) 0.6 (0.3, 1.5) 1.1 (0.5, 2.4) 0.059‡
Cardiopulmonary resuscitation* 32% 10% 53%  0.001
Transfer 60% 63% 56% 0.653
Thrombolytic eligible 95% 98% 93% 0.616
Thrombolytic administered 49% 54% 44% 0.508
GP IIb/IIIa inhibitor 32% 27% 38% 0.457
Inotrope/vasopressor 100% 100% 100% —
Intra-aortic balloon pump 89% 83% 95% 0.155
Stent in culprit artery 34% 37% 32% 0.816
Mechanical ventilation 84% 76% 93% 0.067
30-day survival 54% 100% 7%  0.001
*Before randomization. †Often obtained while on support measures. ‡p value is from the Wilcoxon rank sum test except for age and heart rate which use the Student t test.
GP  glycoprotein; MI  myocardial infarction; PCI  percutaneous coronary intervention.
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50% who had reduced angiographic coronary flow (TIMI
0, 1, 2); this represents 53% of all patients with TIMI 0, 1,
or 2 flow post-PCI. Their 30-day and one-year survival was
47%. Coronary flow after PCI was a significant determinant
of survival (Fig. 3). All survivors had patent (TIMI 2
or 3 flow grade) infarct-related arteries immediately after
PCI; however, patency did not guarantee survival (Table 3).
The PCI success rates by age were 58% in the 12 patients
75 years and 79% in patients 75 years (p  0.15).
One-year survival after PCI was lower in the elderly (17%
vs. 56%, p  0.026).
Despite increasing rates of multivessel PCI, stent place-
ment, and GP IIb/IIIa antagonist use over the five-year
course of the trial, the one-year survival rate for patients
Table 2. Angiographic Findings of Patients Assigned to Early Revascularization and Undergoing
PCI in the SHOCK Trial by One-Year Survival Status (n  82)
Category
All PCI
Patients
One-Year
Survival Survivors
Non-
Survivors
p
Value
Diseased vessels 0.235
1-vessel 19% 60% 22% 15%
2-vessel 21% 59% 24% 18%
3-vessel* 60% 45% 54% 68%
Left main disease (stenosis 50%) 14% 27% 7% 21% 0.111
Culprit vessel 0.314
Left main 5% 25% 3% 8%
Left anterior descending 50% 43% 43% 58%
Right 33% 65% 43% 23%
Left circumflex 9% 57% 10% 8%
Saphenous graft 4% 33% 3% 5%
Jeopardy score 7.0  3.3 — 6.5  3.1 7.6  3.4 0.105
Lesion type (n  78, 78, 40, 38)† 0.174
A 0% 0% 0% 0%
B1 or B2 78% 56% 85% 71%
C 22% 35% 15% 29%
Initial stenosis in culprit vessel (%)‡ 95  8 — 94  8 96  7 0.140
Pre-PCI TIMI flow grade 0.279¶
0 or 1 62% 45% 56% 68%
2 17% 57% 20% 15%
3 21% 59% 24% 17%
2 or 3 38% 58% 44% 32% 0.363#
MR grade (n  34, 34, 20, 14)§ 0.202
None to moderate (grades 0 to 2) 82% 64% 90% 71%
Severe (grades 3 or 4) 18% 33% 10% 29%
Left ventricular ejection fraction (%)
(n  33, 33, 19, 14)§
31  10 — 34  11 27  7 0.025
*Of the 49 patients with three-vessel coronary artery disease, 17 (35%) had 90% stenoses in all three vessels. †p value is for
the comparison of B1 or B2 versus C lesion types. ‡Stenosis by non-quantitative assessment. §Combination of angiographic and
echocardiographic data obtained before PCI and on support. p value is from the Wilcoxon rank sum test. ¶p value is for the
comparison of grade 0 or 1 versus grade 2 versus grade 3 TIMI flow. #p value is for the comparison of grade 0 or 1 versus grade
2 or 3 TIMI flow.
MR  mitral regurgitation, PCI  percutaneous coronary intervention; TIMI  Thrombolysis In Myocardial Infarction.
Table 3. Angiographic Outcome and One-Year Survival After PCI in Patients Assigned to Early Revascularization in the SHOCK
Trial (n  82)
All PCI Patients
One-Year
Survival Survivors Non-Survivors
p Valuen % n % n % n %
Post-PCI TIMI flow grade  0.001*
0 or 1 10 12 10 0 0 0 10 24
2 22 27 22 45 10 24 12 29
3 50 61 50 62 31 76 19 46
2 or 3 72 88 72 57 41 100 31 76 0.001†
Final stenosis (%)‡ 82 36  31 — — 41 26  24 41 46  34 0.011§
PCI success  0.001
Successful 62 76 62 61 38 93 24 59
Unsuccessful 20 24 20 15 3 7 17 41
*p value is for the comparison of grade 0 or 1 versus grade 2 versus grade 3 TIMI flow. †p value is for the comparison of grade 0 or 1 versus grade 2 or 3 TIMI flow. ‡Stenosis
by non-quantitative assessment. §p value is from the Wilcoxon rank sum test.
Abbreviations as in Table 2.
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who underwent PCI was similar over time (Fig. 4). One-
year survival was 55% after single-vessel PCI but only 20%
after a single-stage multivessel procedure (p  0.048).
One-year survival was 38% for eight patients who under-
went emergency coronary bypass surgery within 24 h of
PCI. Among patients undergoing PCI, 18% had severe
mitral regurgitation but did not undergo urgent valve
surgery, and their survival was 33%. In PCI patients without
severe mitral regurgitation, survival was 64% (p  0.202).
Correlates of death. Independent correlates of death at
one year based on multivariate Cox regression analysis are as
follows: increasing age (p  0.001), lower systolic blood
pressure recorded on support measures (p 0.009), increas-
ing time from randomization to PCI (p  0.019), lower
final post-PCI TIMI flow grade (0/1 vs. 2/3) (p  0.001),
and multivessel PCI (p  0.040) (Table 4). There was no
association between time from MI or time from shock to
PCI and outcome. Though time from randomization to
PCI is a strong correlate of death, there were differences
between patients who underwent rapid PCI (0.87 h to
PCI) and delayed PCI (0.87 h) signifying that severity of
illness is contributing to this association. Patients with
delayed PCI tended to be older than those with rapid PCI
(67  10 vs. 63  10 years, p  0.06), have more diabetes
(37% vs. 15%, p  0.038), a trend towards more left main
disease (18% vs. 8%, p  0.19) as well as a trend toward
higher jeopardy score (7.6  3.4 vs. 6.3  3.0, p  0.08),
thus implying that they are a sicker group of patients in our
cohort. When four outliers with long times from random-
ization to PCI (5.4 to 6.5 h) were removed, age, supported
systolic blood pressure, and final TIMI flow remained
significant, but multivessel PCI (p  0.092) and time from
randomization to PCI (p  0.096) were no longer
significant.
Ejection fraction and mitral regurgitation grade were not
found to be correlates of death when included in multivar-
iate modeling, but these were only available for one-third of
the patients. Cardiopulmonary resuscitation was not in-
cluded as it was only available for two-thirds of the patients.
DISCUSSION
Emergency revascularization in the SHOCK Trial was
associated with an increase in one-year survival, consistent
with 132 lives saved per 1,000 patients treated. This
represents a benefit larger than for any other therapy tested
for acute MI (6,8). Percutaneous coronary intervention
constituted the most frequent mode of revascularization
chosen when a strategy of emergency revascularization was
assigned by protocol. In-hospital survival after PCI in the
SHOCK trial was similar to that reported in the SHOCK
registry (54% vs. 56%, respectively) (7,14).
Infarct artery patency. Early reperfusion of an infarct-
related artery is associated with improved outcome in shock
(4,14,15). Thrombolysis results in relatively low rates of
reperfusion in patients in whom shock is already established
(3,16), and the likelihood of sustained reperfusion is higher
with PCI (17–20). Post-PCI patency of the infarct artery is
strongly associated with survival, even after adjustment for
important clinical and hemodynamic characteristics. No
patient who had an occluded infarct artery (TIMI flow
grade 0 or 1) after PCI survived.
Figure 4. Time trends in the interventional management of cardiogenic
shock and one-year survival. A significant increase in the use of multivessel
percutaneous coronary intervention (PCI) (p  0.018), stents, and glyco-
protein IIb/IIIa antagonists (both0.001) was observed. One-year survival
and PCI success rates were similar over time (p  0.889 for survival and
p  0.128 for success).
Figure 2. Relationship of stent implantation in the culprit artery and
one-year survival in SHOCK trial patients assigned to early revasculariza-
tion and undergoing percutaneous coronary intervention.
Figure 3. Relationship of final angiographic culprit artery Thrombolysis In
Myocardial Infarction (TIMI) flow grade after percutaneous coronary
intervention and 30-day survival in SHOCK trial patients assigned to early
revascularization.
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PCI was performed a median of 11 h after the onset of
MI symptoms. It appears that, in the setting of shock, the
benefit of PCI extends beyond the usually accepted 12-h
post-MI window. Importantly, therapy appears effective for
those transferred from primary care hospitals. The apparent
lack of association between earlier times from MI or shock
to PCI and survival may be explained by the use of
intra-aortic balloon pump and thrombolytic agents in al-
most 90% and 50% of patients, respectively, who underwent
PCI and survivor bias, whereby those who did not survive to
the procedure are excluded.
PCI procedure. The success rate of PCI was relatively low
(76%) but consistent with previous retrospective shock
studies (3,4), and not unexpected given that most patients
had diffuse disease, occluded arteries, and were hemody-
namically unstable. This study predates the advent of
widespread stenting in the setting of acute MI. Stents were
used in 34% of patients, mainly to salvage a failed balloon
PCI, and were largely first-generation devices implanted
without the benefit of current adjunctive techniques. De-
spite this, the rate of PCI success was higher in stented than
unstented patients. Similarly, GP IIb/IIIa inhibitor and
thienopyridine use was infrequent but increased during the
nearly six-year trial period. Potentially, the increased use of
stenting and adjunctive therapies that improve coronary
blood flow might further extend the benefits of PCI
(17–21).
Multivessel disease. Although multivessel disease was
present in the majority of patients, most had single-vessel
angioplasty. Percutaneous coronary intervention of the cul-
prit lesion alone has been advocated in the management of
acute MI (3,4). The prevalence of multivessel disease and
the possibility of ischemia at a distance from the infarct zone
and of progressive deterioration in left ventricular function
may argue for a strategy of more complete revascularization
with multivessel PCI or surgery (4,14,17,22).
Although the mode of revascularization was recom-
mended by the protocol on the basis of the extent and
severity of disease, the choice was at the discretion of the
attending physician. It is notable that equivalent survival
with surgery was achieved despite the selection of patients
with more severe disease to undergo this means of revascu-
larization (6). Survival after single-stage multivessel PCI
procedures was disappointing, whether as a result of patient
selection or less satisfactory revascularization. Where the
likelihood of successful PCI is low or relatively complete
revascularization cannot be achieved, emergency surgery
may be preferable to PCI.
Mitral insufficiency. The SHOCK study excluded enroll-
ment of patients in whom the investigator determined that
mitral valve replacement was clinically indicated. Among
enrolled patients who had severe mitral regurgitation and
underwent PCI alone, the one- year survival rate was a
disappointing 33%. Mitral insufficiency is easily missed in
shock patients and should be specifically sought with echo-
cardiography or ventriculography before PCI. Although a
reduction in mitral insufficiency may occur with PCI, this is
unpredictable and infrequent. Severe mitral insufficiency
may warrant early surgical correction (4,14,23).
PCI in the elderly. The SHOCK trial suggested a lack of
benefit for early revascularization in patients 75 years of
age; however, numbers were small, with only 12 PCI
patients 75 years of age. Although PCI tended to be less
often successful in elderly patients, successful PCI is asso-
ciated with increased survival. Dzavik et al. (24) reported
higher survival rates for the 17% of patients 75 years of
age in the SHOCK registry who were clinically selected to
undergo early revascularization compared with those with
late or no revascularization. This survival rate (52%) is
comparable to the larger cohort of patients75 years of age
who underwent early revascularization in the registry. It
seems reasonable to conclude that early revascularization
may be appropriate for selected elderly patients and that
management must be individualized.
Study limitations. Although patient selection bias is of
concern (2,4,14), the SHOCK trial adhered to strict criteria
for the diagnosis of shock and randomization-mandated
early revascularization. Patients appeared representative of
the larger, unselected population in the SHOCK registry
(2,14), although by design those who were not suitable for
an aggressive strategy (e.g., life-shortening illnesses) were
not enrolled (7,8). Only 40% of patients assigned to emer-
gency revascularization had a left ventricular angiogram
performed, and therefore associations between survival and
ejection fraction and mitral regurgitation are possibly bi-
ased. It is likely that the association of certain characteristics
and survival was not significant because of the limited
number of patients. This study largely predates the advent
of widespread stenting and the use of GP IIb/IIIa antago-
nists (17,20,25).
Table 4. Multivariate Cox Regression Results for One-Year Survival*
Parameter
Parameter
Estimate
Standard
Error
Hazard Ratio
(95% CI) p Value
Age (yrs) 0.077 0.020 2.17 (1.46, 3.22)†  0.001
Systolic blood pressure (mm Hg)‡ 0.025 0.010 0.78 (0.65, 0.94)† 0.009
Time from randomization to PCI (h) 0.253 0.108 1.29 (1.04, 1.59) 0.019
Final post-PCI TIMI flow (0/1 vs. 2/3) 2.385 0.614 10.86 (3.26, 36.20)  0.001
Multivessel PCI 1.012 0.494 2.75 (1.05, 7.25) 0.040
*Variables with significance p  0.05 are shown (n  76). †The hazard ratios and confidence intervals for age and systolic blood
pressure are per 10-year or 10 mm Hg increase, respectively. ‡Measured while on support.
CI  confidence interval; PCI  percutaneous coronary intervention; TIMI  Thrombolysis In Myocardial Infarction.
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Conclusion. In the SHOCK trial, successful early restora-
tion of coronary blood flow is a major predictor of survival
and an important therapeutic goal. Although very early
intervention is preferable, in the setting of shock the benefit
of reperfusion appears to extend beyond the generally
accepted 12-h post-MI window. Surgery should be consid-
ered in shock patients with severe mitral insufficiency or
multivessel disease not amenable to relatively complete
percutaneous revascularization.
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